KRED

Tuesday, March 21, 2017

SutroVax Announces Closing of $64M via Series B Financing

http://ift.tt/2mPMQWK

SutroVax is an independent vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. The company is leveraging its exclusive license to Sutro Biopharma's Xpress CF platform to perform cell-free protein synthesis and site-specific conjugation for the field of vaccines. www.sutrovax.comFOSTER CITY, Calif., March 21, 2017 /PRNewswire/ -- SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of a $60 million Series B...




March 21, 2017 at 04:22PM

http://ift.tt/2mojwdO

from

http://ift.tt/2mojwdO